Electroceuticals / Bioelectronic Medicine
TENS / Microcurrent / FSM (incl. SCENAR / DENAS) Conventional bioelectric stimulation with a real, modest evidence base for pain (the one success branch of the Soviet 'field-medicine' lineage). Systemic / disease claims beyond pain are overreach.
Origin & lineage
Electrostimulation lineage, pain rehab; SCENAR/DENAS = impedance-adaptive Soviet branch.
Claimed mechanism
Weak electrical current modulates nerve / pain signalling (gate-control, endogenous opioids); SCENAR/DENAS adapt to skin impedance.
Plausibility
Plausible analgesia; weak for systemic claims.
Evidence — grade A/B
A/B for pain; drops to C for broad / systemic claims.
Market
Makers: Omron; NeuroMetrix (Quell); Zynex; Empi; RITM (SCENAR); DENAS.Models: TENS units; Quell; SCENAR; DENAS; FSM.Price: Omron ~$50; pro $500–5K; FSM $1–5K; SCENAR ~$150–2,500.
Kernel — keep vs set aside Keep — real substrate
Conventional bioelectric stimulation — real, modest evidence base for pain.
Set aside — claim
Not 'quantum'; systemic / disease claims beyond pain are FTC-actionable overreach.
Regulatory status by jurisdiction Registration or clearance is a market-access fact, never proof of efficacy.
US — FDA TENS FDA-cleared OTC analgesia; SCENAR Class II 510(k) for pain (2010); FTC if systemic overclaim. EU — MDR CE marked. Russia MoH registered (SCENAR / DENAS). China — NMPA Not found. Australia — TGA ARTG AustL 169570 (SCENAR).
Sources No verified primary source available — claims carried as unverified ; not fabricated.
This is an evidence atlas — a map, not a marketplace and not medical advice. It reports the mechanism, evidence grade, and regulatory status of physical and energy-based modalities, including the views and claims of third parties, with sources cited where they exist. Regulatory registration or clearance is a market-access fact, never proof of efficacy. Nothing here is an endorsement, a diagnosis, or a treatment recommendation. Consult a qualified clinician before making any health decision.
Evidence grades reflect the position of scientific consensus on the available evidence and may change. All trademarks belong to their respective owners; cited material remains the property of its authors.
© 2024–2026 devices.longevity.one